Linifanib: Receptor tyrosine kinase inhibitor oncolytic

Drugs of the Future

Volumn 35, Issue 2, 2010, Pages 106-112

  Haddley, K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 [4 (3 AMINO 1H INDAZOL 4 YL)PHENYL] 3 (2 FLUORO 5 METHYLPHENYL)UREA; AL 39324; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CYTARABINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; LINIFANIB; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; RAPAMYCIN; RG 3635; SORAFENIB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; VORINOSTAT;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; ASTHENIA; AUTOPHOSPHORYLATION; CANCER INHIBITION; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONCENTRATION RESPONSE; CONTRAST ENHANCEMENT; DIARRHEA; DISEASE MARKER; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SPECIFICITY; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME INHIBITION; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; IC 50; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; MYALGIA; NONHUMAN; OVERALL SURVIVAL; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; PROTEINURIA; RASH; SKIN TOXICITY; TUMOR XENOGRAFT;

EID: 84930540525     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2010.035.02.1440660     Document Type: Article

References (48)

1. Davidsen, S.K., Hartandi, K., Ji, Z., Dai, Y., Ericsson, A.M., Michaelides, M.R. (Abbott Laboratories Inc.). Indazole, benzisoxazole, and benzisothiazole kinase inhibitors. EP 1638941, JP 2007500226, US 2004235892, US 2005020603, WO 2004113304.
2. Dai, Y., Hartandi, K., Ji, Z. et al. Discovery of N-(4-(3-amino-1H- indazol-4-yl)phenyl)-N′-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor. J Med Chem 2007, 50(7): 1584-97.
3. Kruger, A.W., Rozema, M.J., Chu-Kung, A. et al. The discovery and development of a safe, practical synthesis of ABT-869. Org Process Res Dev 2009, 13(6): 1419.
4. Hanahan, D., Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100(1): 57-70.
5. Bergers, G., Benjamin, L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003, 3: 401-10.
6. Ferrara, N., Gerber, H.P., LeCouter, J. The biology of VEGF and its receptors. Nat Med 2003, 9(6): 669-76.
7. Zhou, J., Mauerer, K., Farina, L., Gribben, J.G. The role of the tumor microenvironment in hematological malignancies and implications for therapy. Front Biosci 2005, 1(10): 1581-96.
8. Fedi, P., Tronick, S.R., Aaronson, S.A. In: Growth Factors In Cancer Medicine. Holland, J.F., Bast, R.C., Morton, D.L., Frei, E., Kufe, D.W., Weichselbaum, R.R. (Eds.). Baltimore: Williams and Wilkins, 1997, 41-64.
9. Los, M., Roodhart, J.M., Voest, E.E. Target practice: Lessons from phase III trials with bevocizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 2007, 12(4): 443-5.
10. Roboz, G.J., Giles, F.J., List, A.F. et al. Phase 1 study of PTK787/ZK222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Leukemia 2006, 20(6): 952-7.
11. Albert, D.H., Tapang, P., Magoc, T.J. et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 2006, 5(4): 995-1066.
12. Albert, D.H., Tapang, P., Magoc, T.J. et al. Preclinical activity of ABT-869, a multi-targeted receptor tyrosine kinase inhibitor. Proc Am Assoc Cancer Res (AACR) 2005, 46: Abst 676.
13. Dai, Y., Guo, Y., Frey, R.R. et al. Thienopyrimidine ureas as novel potent multitargeted receptor tyrosine kinase (RTK) inhibitors. J Med Chem 2005, 48(19): 6066-83.
14. Guo, J., Marcotte, P.A., McCall, J.O. et al. Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. Mol Cancer Ther 2006, 5(4): 1007-13.
15. Guo, J., Dai, Y., Bui, M.H. et al. Cellular activity of ABT-869 against colony-stimulating-factor-1 receptor (CSF-1R) in macrophage-like cell lines. Proc Am Assoc Cancer Res (AACR) 2009, 50: Abst 1789.
16. Shankar, D.B., Li, J., Tapang, P. et al. ABT-869, a multitargeted receptor tyrosine kinase inhibitor: Inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. Blood 2007, 109(8): 3400-8.
17. Li, J., Pease, L.J., Tapang, P. et al. ABT-869 a novel multi-targeted receptor tyrosine kinase inhibitor: Characterization of FLT3 phosphorylation in a model of acute myelogenous leukemia. Proc Am Assoc Cancer Res (AACR) 2005, 46: Abst 5981.
18. Hernandez, J.E., Li, J., Wei, R.-Q. et al. Multi-targeted receptor tyrosine kinase inhibitor, ABT-869, induces apoptosis and inhibition of proliferation of Ba/F3 FLI-3 ITD mutant cells. Blood 2007, 110(11): Abst 1589.
19. Hernandez, J.E., Zape, J.P., Landaw, E.M., Glaser, K.B., Fu, C., Sakamoto, K.M. Multi-targeted receptor tyrosine kinase inhibitor, ABT-869, induces apoptosis and suppresses proliferation of Ba/F3 FLT-3 ITD mutant cells in vitro and in vivo through inhibition of FLT3 and AKT. Proc Am Assoc Cancer Res (AACR) 2009, 50: Abst 3727.
20. Stavropoulos, J.A., Meulbroek, J.A., Niquette, A.L. et al. Preclinical activity of ABT-869, a novel receptor tyrosine kinase inhibitor, alone or in combination with paclitaxel. 41st Annu Meet Am Soc Clin Oncol (ASCO) (May 13-17, Orlando) 2005, Abst 3175.
21. Phase 2 study of ABT-869 in combination with paclitaxel versus paclitaxel alone to treat metastatic breast cancer (NCT00645177). ClinicalTrials.gov Web site, January 15, 2010.
22. Zhou, J., Bi, C., Liu, S.-C. et al. In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor. Leuk Res 2008, 32(7): 1091-100.
23. Jasinghe, V.J., Xie, Z., Zhou, J. et al. ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft. J Hepatol 2008, 49(6): 985-7.
24. Zhou, J., Pan, M., Xie, Z. et al. Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway. Leukemia 2008, 22(1): 138-46.
25. Steinberg, J., Tan, E., Wei-Peng, Y. et al. Preliminary analysis of ABT-869 safety, pharmacokinetics and efficacy in three phase 2 solid tumor studies. Ann Oncol 2008, 19(Suppl. 8): Abst 477P.
26. Gupta, N., Diderichsen, P.M., Steinberg, J., Ricker, J.L., Humerickhouse, R., Awni, W., Pradhan, R. Population pharmacokinetic (PK) analysis of ABT-869 in solid tumors and acute myelogenous leukemia (AML) patients. J Clin Oncol 2009, 27(15, Suppl.): Abst 3567.
27. Chiu, Y., Yan, Z., Gupta, N. et al. Exposure-response analysis to identify ABT-869 dose in hepatocellular carcinoma (HCC) patients. Eur J Cancer Suppl 2009, 7(2): Abst P-6613.
28. A phase 1 study of ABT-869 in subjects with solid tumors (NCT00718380). ClinicalTrials.gov Web site, January 15, 2010.
29. Goh, B.C., Thng, CH., Sukri, N. et al. Phase I study of ABT869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. Eur J Cancer Suppl 2006, 4(12): Abst 108.
30. Wong, C.I., Thng, C.H., Soo, R. et al. Phase I and biomarker study of ABT869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J Clin Oncol 2007, 25(18, Suppl.): Abst 3519.
31. Wong, C.I., Koh, T.S., Soo, R. et al. Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J Clin Oncol 2009, 27(28): 4718-26.
32. Humerickhouse, R., Gupta, N., Goh, B. et al. Phase 1 comparison of pharmacokinetics, safety and efficacy with low versus high doses of ABT-869 in refractory solid tumors. Ann Oncol 2008, 19(Suppl. 8): Abst 476P.
33. Study of ABT-869 in subjects with advanced non-small cell lung cancer (NSCLC) (NCT00517790). ClinicalTrials.gov Web site, January 15, 2010.
34. Tan, E., Salgia, R., Besse, B. et al. ABT-869 in non-small cell lung cancer (NSCLC): Interim results. J Clin Oncol 2009, 27(15, Suppl.): Abst 8074.
35. Study of ABT-869 in subjects with advanced renal cell carcinoma who have previously received treatment with sunitinib (NCT00486538). ClinicalTrials.gov Web site, January 15, 2010.
36. Tannir, N., Wong, Y., Kollmannsberger, C. et al. Phase 2 results of ABT-869 treatment in patients with advanced renal cell cancer (RCC) after sunitinib failure. Eur J Cancer Suppl 2009, 7(2): Abst PD-7109.
37. Tannir, N., Wong, Y., Kollmannsberger, C. et al. Phase II trial of ABT-869 in advanced renal cell cancer (RCC) after sunitinib failure: Efficacy and safety results. J Clin Oncol 2009, 27(15, Suppl.): Abst 5036.
38. Phase 2 study of ABT-869 in advanced hepatocellular carcinoma (HCC) (NCT00517920). ClinicalTrials.gov Web site, January 15, 2010.
39. Toh, H., Chen, P., Carr, B.I. et al. A phase II study of ABT-869 in hepatocellular carcinoma (HCC): Interim analysis. J Clin Oncol 2009, 27(15, Suppl.): Abst 4581.
40. Yong, W.-P., Chen, R-J., Knox, J. et al. Open-label, multicenter phase 2 trial of ABT-869 in advanced hepatocellular carcinoma (HCC) patients: Prognostic factors. 3rd Annu Conf Int Liver Cancer Assoc (ILCA) (Sept 4-6, Milan) 2009, Abst 0-034.
41. Steinberg, J., Ricker, J.R., Wong, Y-N. et al. ABT-869 response monitoring with DCE-MRI, PET and CT imaging in advanced solid tumor cancer patients. Proc Am Assoc Cancer Res (AACR) 2009, 50: Abst 5629.
42. Soo, R., Thng, C-H., Sukri, N. et al. ABT-869, a multiple tyrosine kinase inhibitor, has promising activity in patients with non-small cell lung cancer (NSCLC) in a phase I dose escalation study. J Thorac Oncol 2007, 2(8, Suppl. 4): Abst PD3-1-1.
43. Soo, R.A., McKeegan, E., Chen, C.S. et al. The effect of varying doses of ABT-869 on biomarkers of angiogenesis and their correlation with pharmacodynamic outcome. J Clin Oncol 2008, 26(15, Suppl.): Abst 14535.
44. Pharmacokinetic study to evaluate effect of food and diurnal variation on ABT-869 (NCT00733187). ClinicalTrials.gov Web site, January 15, 2010.
45. Efficacy and tolerability of ABT-869 versus sorafenib in advanced hepatocellular carcinoma (HCC) (NCT01009593). ClinicalTrials.gov Web site, January 15, 2010.
46. Study of carboplatin/paclitaxel in combination with ABT-869 in subjects with advanced or metastatic non-small cell lung cancer (NSCLC) (NCT00716534). ClinicalTrials.gov Web site, January 15, 2010.
47. Ramalingam, S., Owonikoko, T., Khuri, F. et al. Phase 2 study of ABT-869 in combination with carboplatin/paclitaxel (CP) in patients with advanced or metastatic non-small cell lung cancer (NSCLC): Lead-in cohort results. J Thorac Oncol 2009, 4(9, Suppl. 1): Abst P1.234.
48. Phase 2 study of ABT-869 in combination with mFOLFOX6 versus bevacizumab in combination with mFOLFOX6 to treat advanced colorectal cancer (NCT00707889). ClinicalTrials.gov Web site, January 15, 2010.